{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T10:04:00Z","timestamp":1791626640417,"version":"4.3.4"},"reference-count":58,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ANZ Journal of Surgery"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most patients with localized bladder cancer are initially managed with endoscopic resection. For high\u2010grade nonmuscle invasive bladder cancer (NMIBC), intravesical Bacillus Calmette\u2010Guerin (BCG) therapy is the gold standard adjuvant treatment. However, 30%\u201340% of patients fail BCG treatment with lack of response or disease relapse. An understudied area of treatment failure is BCG intolerance, where patients drop out of treatment due to adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine the incidence and underlying reasons for BCG intolerance among adult patients with NMIBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a search on Embase, MEDLINE, and Cochrane Central Register of Controlled Trials for studies from January 1, 1974 to January 10, 2023, retrieving 3340 articles. Two authors independently conducted screening and data extraction with Preferred Reporting Items for Systematic Reviews and Meta\u2010analyses guidelines. Inclusion criteria include English\u2010language studies reporting dropout rates and reasons for discontinuation of BCG therapy in NMIBC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BCG dropout rates reported among the 28 included studies varied widely from 0% to 52% (estimated summary proportion 12.8%, 95% CI 9%\u201317%). There was significant heterogeneity in study design. Subgroup analyses show a dose\u2010dependent effect on dropout rates (3.3% vs. 20%,\n                      <jats:italic>X<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200983.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009&lt;\u20092.2\u2009\u00d7\u200910\n                      <jats:sup>\u221216<\/jats:sup>\n                      ). Dropout rates vary with BCG strains: the Connaught strain had the highest at 21.1%, while the Pasteur strain had 2%. Clinical outcomes for BCG intolerance are not widely reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dropout rates due to BCG intolerance average 12.8%. As cessation of treatment could lead to an increased risk in progression or recurrence of disease, strategies to mitigate BCG intolerance would be valuable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ans.70281","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:36:42Z","timestamp":1755693402000},"page":"2460-2467","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["<scp>BCG<\/scp>\n                    Intolerance in Nonmuscle Invasive Bladder Cancer\u2014A Systematic Review"],"prefix":"10.1111","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-0673","authenticated-orcid":false,"given":"Claris","family":"Oh","sequence":"first","affiliation":[{"name":"College of Medicine and Public Health, Flinders University  Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Bourlotos","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders University  Adelaide Australia"},{"name":"Flinders Health and Medical Research Institute, Flinders University  Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O'Callaghan","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders University  Adelaide Australia"},{"name":"Urology Unit, Flinders Medical Centre  Adelaide Australia"},{"name":"Discipline of Medicine, The University of Adelaide  Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Grundy","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders University  Adelaide Australia"},{"name":"Flinders Health and Medical Research Institute, Flinders University  Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hong","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders University  Adelaide Australia"},{"name":"Urology Unit, Flinders Medical Centre  Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17601"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1170124"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.777"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.016"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.1196"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.07.021"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2018.1538162"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0302\u20102838(03)00357\u20109"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.017"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022\u20105347(05)67707\u20105"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.08.066"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"e_1_2_10_14_1","unstructured":"C.Oh G.Bourlotos L.Grundy et\u00a0al. \u201cBCG Intolerance in Non\u2010Muscle Invasive Bladder Cancer: A Systematic Review \u201d2023PROSPERO 2023 CRD42023495015 https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42023495015."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_16_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5","author":"Higgins J.","year":"2024"},{"key":"e_1_2_10_17_1","unstructured":"Team RC \u201cR: A Language and Environment for Statistical Computing \u201d2022accessed September 22 2024 http:\/\/www.R\u2010project.org."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","unstructured":"A.Picard D.Champetier P.Perrin et\u00a0al. \u201cDiscontinuance of BCG Instillation for Non\u2010Muscle Invasive Bladder Cancer: Prognostic Impact on Recurrence \u201dIn: European Urology Supplements 2010.","DOI":"10.1016\/S1569-9056(10)60193-5"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464\u2010410X.2003.04764.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479\u20105876\u20108\u201054"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.02.1140"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13474"},{"key":"e_1_2_10_24_1","unstructured":"S.Fornia S.Ferretti D.Campobasso et\u00a0al. \u201cBaciilus Calmette\u2010Guerin: Treatment for Superficial Treatment for Superficial Transitional Cell Carcinoma (TCC) of the Bladder \u201d2010."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys097"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464\u2010410x.2002.02722.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/cu9.0000000000000134"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2021.05.002"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12301\u2010020\u201000099\u20106"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13193\u2010021\u201001439\u2010w"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.12.039"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2020168"},{"key":"e_1_2_10_33_1","unstructured":"V.Hoe F.Harley S.Wallace et\u00a0al. \u201cReview of Bacillus Calmette\u2010Guerin (BCG) Tolerability and Complications of Intravesical Therapy for Non\u2010Muscle Invasive Bladder Cancer (NMIBC) Over a 4 Year Period \u201d202040th Congress of the Societe Internationale d'Urologie."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000049765"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s101470200042"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0090\u20104295(98)00446\u20104"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000823.06"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870801)60:3<326::AID-CNCR2820600309>3.0.CO;2-5"},{"key":"e_1_2_10_39_1","unstructured":"G. G.SandeshandB.Sudarshan \u201cImmunotherapy in NMIBC Our Experience in 20 Cases \u201d2017."},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1159\/000273461"},{"key":"e_1_2_10_41_1","unstructured":"D.Yamada R.Muneishi H.Nakatsuka et\u00a0al. \u201cTreatment Efficacy and Tolerability of Intravesical Bacillus Calmette\u2010Guerin (BCG): Six\u2010Weekly Induction Course and Once Every Two Months for One Year Maintenance Protocol in High Risk Non\u2010Muscle Invasive Bladder Cancer (NMIBC) \u201d2014."},{"key":"e_1_2_10_42_1","first-page":"844","article-title":"Long\u2010Term Outcome of Intravesical Bacillus Calmette\u2010Gu\u00e9rin Therapy With Maintenance for Urinary Bladder Carcinoma in Situ: About 47 Cases","volume":"94","author":"Sallami S.","year":"2016","journal-title":"Tunisie Medicale"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445\u20102197.2004.02941.x"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyi111"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aju.2015.09.005"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.037"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.58"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464\u2010410x.2001.02306.x"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.04.038"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20210340"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuroe.2022.08.005"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.04.003"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2013.33.265"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0022\u20105347(05)64273\u20105"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.01.084"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.01.086"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.061"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13538"},{"key":"e_1_2_10_59_1","first-page":"423","article-title":"Failure of Bacillus Calmette\u2010Gu\u00e9rin Therapy in Non\u2010Muscle\u2010Invasive Bladder Cancer: Definition and Treatment Options","volume":"69","author":"Gual Frau J.","year":"2016","journal-title":"Archivos Espanoles De Urologia"}],"container-title":["ANZ Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ans.70281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T07:53:18Z","timestamp":1766217198000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ans.70281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/ans.70281"],"URL":"https:\/\/doi.org\/10.1111\/ans.70281","archive":["Portico"],"relation":{},"ISSN":["1445-1433","1445-2197"],"issn-type":[{"value":"1445-1433","type":"print"},{"value":"1445-2197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"2025-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}